Our Approved Medicines
Our program began as a small research project in 1998. Vertex is investigating numerous cystic fibrosis (CF) compounds and is focused on developing medicines for all people with CF. To date, we have four CF medicines with regulatory approvals in many countries, including the UK.
Great Britain
SYMKEVI® ▼ (tezacaftor/ivacaftor)
ORKAMBI® ▼ (lumacaftor/ivacaftor)
KAFTRIO® ▼ (ivacaftor/tezacaftor/elexacaftor)
Northern Ireland
SYMKEVI® ▼ (tezacaftor/ivacaftor)
ORKAMBI® ▼ (lumacaftor/ivacaftor)
KAFTRIO® ▼ (ivacaftor/tezacaftor/elexacaftor)
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. You can also report side effects directly via the Yellow Card Scheme: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
June 2021
UK-20-2100036